Literature DB >> 24900073

Detectability of T-Measurable Diseases in Advanced Gastric Cancer on FDG PET-CT.

Sun Young Oh1, Gi Jeong Cheon1, Young Chul Kim1, Eugene Jeong1, Seungeun Kim1, Jae-Gol Choe1.   

Abstract

PURPOSE: Usefulness of FDG PET-CT in monitoring response in locally advanced gastric cancer has been reported. The purpose of this study was to evaluate the related factors to detect measurable diseases in advanced gastric cancer on FDG PET-CT.
METHODS: We retrospectively reviewed 38 patients diagnosed as having advanced gastric cancer. We defined the measurable diseases when there was visualized tumor of which maximum standardized uptake value (SUVmax) was higher than 1.35*SUVmax of liver + 2*SD of liver SUV. We evaluated what kinds of factors from the clinicopathologic features were related to identifying measurable diseases.
RESULTS: Of 38 patients with advanced gastric cancer, 18 (50 %) had measurable tumors on FDG PET-CT. Measurable tumors were significantly more frequent in well or moderately differentiated adenocarcinoma (70.5 % vs 35.3 %, p < 0.05), in the tumors located at antrum or angle (66.7 % vs 29.4 %, p < 0.05) and in the elderly group (age of 55 years old or more, 72.0 % vs 8.3 %, p < 0.001) than the others, respectively. By multivariate analysis, age at diagnosis was the only independent predictor for the measurable disease on FDG PET-CT.
CONCLUSION: We found that age at diagnosis, as well as histologic types and location of tumors, were the affecting factors to detect measurable disease on FDG PET-CT in patients with advanced gastric cancer. Our study suggests that elderly patients of age of 55 years old or more can frequently have T-measurable disease on FDG PET-CT in advanced gastric cancer and FDG PET-CT will be helpful to monitor measurable disease.

Entities:  

Keywords:  Advanced gastric cancer; Affecting factor; Age at diagnosis; FDG PET-CT; Measurable disease

Year:  2012        PMID: 24900073      PMCID: PMC4043066          DOI: 10.1007/s13139-012-0149-5

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  16 in total

1.  An analysis of the physiological FDG uptake pattern in the stomach.

Authors:  Hirofumi Koga; Masayuki Sasaki; Yasuo Kuwabara; Kiyohisa Hiraka; Makoto Nakagawa; Koichiro Abe; Koichiro Kaneko; Kazutaka Hayashi; Hiroshi Honda
Journal:  Ann Nucl Med       Date:  2003-12       Impact factor: 2.668

2.  Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging.

Authors:  W A Weber; K Ott; K Becker; H J Dittler; H Helmberger; N E Avril; G Meisetschläger; R Busch; J R Siewert; M Schwaiger; U Fink
Journal:  J Clin Oncol       Date:  2001-06-15       Impact factor: 44.544

3.  The role of gastric distention in differentiating recurrent tumor from physiologic uptake in the remnant stomach on 18F-FDG PET.

Authors:  Mijin Yun; Hyun Seok Choi; Eunhye Yoo; Jung Kyun Bong; Young Hoon Ryu; Jong Doo Lee
Journal:  J Nucl Med       Date:  2005-06       Impact factor: 10.057

4.  Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.

Authors:  Katja Ott; Wolfgang A Weber; Florian Lordick; Karen Becker; Raymonde Busch; Ken Herrmann; Hinrich Wieder; Ulrich Fink; Markus Schwaiger; Jörg-Rüdiger Siewert
Journal:  J Clin Oncol       Date:  2006-09-11       Impact factor: 44.544

Review 5.  Gastric carcinoma in young adults.

Authors:  A Kokkola; P Sipponen
Journal:  Hepatogastroenterology       Date:  2001 Nov-Dec

Review 6.  Early onset gastric cancer: on the road to unraveling gastric carcinogenesis.

Authors:  Anya N Milne; Robert Sitarz; Ralph Carvalho; Fatima Carneiro; G Johan A Offerhaus
Journal:  Curr Mol Med       Date:  2007-02       Impact factor: 2.222

7.  Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study.

Authors:  Katja Ott; Ken Herrmann; Florian Lordick; Hinrich Wieder; Wolfgang A Weber; Karen Becker; Andreas K Buck; Martin Dobritz; Ulrich Fink; Kurt Ulm; Tibor Schuster; Markus Schwaiger; Jörg-Rüdiger Siewert; Bernd J Krause
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

8.  Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial.

Authors:  Katja Ott; Ulrich Fink; Karen Becker; Alexander Stahl; Hans-Joachim Dittler; Raymonde Busch; Hubert Stein; Florian Lordick; Thomas Link; Markus Schwaiger; Jörg-Rüdiger Siewert; Wolfgang A Weber
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

9.  PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.

Authors:  Florian Lordick; Katja Ott; Bernd-Joachim Krause; Wolfgang A Weber; Karen Becker; Hubert J Stein; Sylvie Lorenzen; Tibor Schuster; Hinrich Wieder; Ken Herrmann; Rainer Bredenkamp; Heinz Höfler; Ulrich Fink; Christian Peschel; Markus Schwaiger; Jörg R Siewert
Journal:  Lancet Oncol       Date:  2007-09       Impact factor: 41.316

Review 10.  Phenotypic and genotypic events in gastric carcinogenesis.

Authors:  P Correa; Y H Shiao
Journal:  Cancer Res       Date:  1994-04-01       Impact factor: 12.701

View more
  2 in total

1.  Dual time point [18F]Flurodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computed Tomography (CT) with water gastric distension in differentiation between malignant and benign gastric lesions.

Authors:  Hussein Farghaly; Mohamed Alshareef; Abdullah Alqarni; Mohamed Sayed; Hatem Nasr
Journal:  Eur J Radiol Open       Date:  2020-09-07

2.  Clinicopathologic parameters associated with the FDG-avidity in staging of early gastric cancer using 18F-FDG PET.

Authors:  Joon-Kee Yoon; Cheulsu Byun; Kyung Sook Jo; Hun Hur; Kee Myung Lee; Seon Kyo Lim; Dakeun Lee; Su Jin Lee; Young-Sil An; Sang-Uk Han
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.